<DOC>
	<DOCNO>NCT02711410</DOCNO>
	<brief_summary>Background : Clopidogrel , antiplatelet prodrug , widely use prevention recurrent cardiovascular event . CYP2C19 one crucial enzymes activation clopidogrel . Recent study , mostly do cardiovascular patient , show association CYP2C19 genotypes recurrent cardiovascular event . However , prospective data impact genetic variant stroke patient limited . Methods : Five hundred eighteen Japanese non-acute stroke patient treat clopidogrel register 14 institution . Three CYP2C19 variant ( CYP2C19*2 , *3 , *17 ) genotyped patient classify three clopidogrel metabolizer group infer CYP2C19 genotype : extensive ( EM : *1/*1 ) , intermediate ( IM : *1/*2 *1/*3 ) , poor ( PM : *2/*2 , *2/*3 , *3/*3 ) . The CYP2C19*17 carrier exclude analysis . The antiplatelet effect clopidogrel assessed Adenosine diphosphate ( ADP ) -induced platelet aggregation vasodilator-stimulated phosphoprotein ( VASP ) phosphorylation , express VASP index . The endpoint composite incidence stroke , transient ischemic attack , myocardial infarction , revascularization , thromboembolic disease , cardiovascular death 2 year follow-up .</brief_summary>
	<brief_title>The Influence CYP2C19 Polymorphism Clinical Outcomes Stroke Patients</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Patients receive longterm clopidogrel therapy ( day least one month ) minimum onemonth interval enrollment last cerebral ischemic TIA event . Males female age 20 year old prescribe clopidogrel secondary prevention cerebral infarction transient ischemic attack willing able give write informed consent . Malignancies Congenital bleeding tendency Atrial fibrillation Concomitant use oral anticoagulant agent platelet count &lt; 100 x 109/L &gt; 450 x 109/L within 3 month enrollment Modified rankin scale &gt; 4</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>